Adjuvant effect of HER-2/neu-specific adenoviral vector stimulating CD8+ T and natural killer cell responses on anti-HER-2/neu antibody therapy for well-established breast tumors in HER-2/neu transgenic mice

Cancer Gene Therapy

Volumn 18, Issue 7, 2011, Pages 489-499

  Chen, Y ^a   Xie, Y ^a   Chan, T ^a   Sami, A ^b   Ahmed, S ^b   Liu, Q ^c   Xiang, J ^a,b  

^a SASKATCHEWAN CANCER AGENCY   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

^c UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

adenoviral vaccine; antibody therapy; breast cancer; CD8+ CTL; HER 2 neu; NK

Indexed keywords

ADENOVIRUS VECTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; OVALBUMIN;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOGENESIS; BREAST TUMOR; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER STAGING; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; IMMUNE RESPONSE; MELANOMA; MOUSE; NATURAL KILLER CELL; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; TUMOR IMMUNITY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; KILLER CELLS, NATURAL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; OVALBUMIN; RATS; RECEPTOR, ERBB-2;

ADENOVIRIDAE; MUS; MUS MUSCULUS;

EID: 79959376450     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2011.18     Document Type: Article

References (82)

1. Schechter AL, Hung MC, Vaidyanathan L, Weinberg RA, Yang-Feng TL, Francke U et al. The neu gene: an erbBhomologous gene distinct from and unlinked to the gene encoding the EGF receptor. Science 1985; 229: 976-978. (Pubitemid 16248489)
2. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-712. (Pubitemid 19147683)
3. Bargmann CI, Hung MC, Weinberg RA. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 1986; 319: 226-230. (Pubitemid 16128785)
4. Pupa SM, Menard S, Andreola S, Colnaghi MI. Antibody response against the c-erbB-2 oncoprotein in breast carcinoma patients. Cancer Res 1993; 53: 5864-5866. (Pubitemid 24006150)
5. Disis ML, Knutson KL, Schiffman K, Rinn K, McNeel DG. Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer. Breast Cancer Res Treat 2000; 62: 245-252.
6. Peoples GE, Goedegebuure PS, Smith R, Linehan DC, Yoshino I, Eberlein TJ. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neuderived peptide. Proc Natl Acad Sci USA 1995; 92: 432-436.
7. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182. (Pubitemid 17231334)
8. Gonzalez-Angulo AM, Hortobagyi GN, Esteva FJ. Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer. Oncologist 2006; 11: 857-867. (Pubitemid 44373758)
9. Nahta R, Esteva FJ. Herceptin: mechanisms of action and resistance. Cancer Lett 2006; 232: 123-138. (Pubitemid 43170962)
10. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007; 12: 395-402. (Pubitemid 47539306)
11. Nahta R, Esteva FJ. HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res 2006; 8: 215.
12. Ho WY, Yee C, Greenberg PD. Adoptive therapy with CD8(+) T cells: it may get by with a little help from its friends. J Clin Invest 2002; 110: 1415-1417. (Pubitemid 35396912)
13. Lara-Tejero M, Pamer EG. T cell responses to Listeria monocytogenes. Curr Opin Microbiol 2004; 7: 45-50. (Pubitemid 38228434)
14. Wherry EJ, Ahmed R. Memory CD8 T-cell differentiation during viral infection. J Virol 2004; 78: 5535-5545. (Pubitemid 38661640)
15. Berzofsky JA, Terabe M, Oh S, Belyakov IM, Ahlers JD, Janik JE et al. Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J Clin Invest 2004; 113: 1515-1525. (Pubitemid 39071672)
16. Serbina N, Pamer EG. Quantitative studies of CD8+ T-cell responses during microbial infection. Curr Opin Immunol 2003; 15: 436-442. (Pubitemid 36930081)
17. Bonnet MC, Tartaglia J, Verdier F, Kourilsky P, Lindberg A, Klein M et al. Recombinant viruses as a tool for therapeutic vaccination against human cancers. Immunol Lett 2000; 74: 11-25.
18. Harrop R, John J, Carroll MW. Recombinant viral vectors: cancer vaccines. Adv Drug Deliv Rev 2006; 58: 931-947. (Pubitemid 44709263)
19. Muruve DA, Cotter MJ, Zaiss AK, White LR, Liu Q, Chan T et al. Helper-dependent adenovirus vectors elicit intact innate but attenuated adaptive host immune responses in vivo. J Virol 2004; 78: 5966-5972. (Pubitemid 38661684)
20. Ng P, Parks RJ, Cummings DT, Evelegh CM, Sankar U, Graham FL. A high-efficiency Cre/loxP-based system for construction of adenoviral vectors. Hum Gene Ther 1999; 10: 2667-2672.
21. Sullivan NJ, Geisbert TW, Geisbert JB, Xu L, Yang ZY, Roederer M et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 2003; 424: 681-684. (Pubitemid 36987993)
22. Gao W, Tamin A, Soloff A, D'Aiuto L, Nwanegbo E, Robbins PD et al. Effects of a SARS-associated coronavirus vaccine in monkeys. Lancet 2003; 362: 1895-1896. (Pubitemid 37518507)
23. Sumida SM, Truitt DM, Kishko MG, Arthur JC, Jackson SS, Gorgone DA et al. Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors. J Virol 2004; 78: 2666-2673. (Pubitemid 38314325)
24. Santra S, Seaman MS, Xu L, Barouch DH, Lord CI, Lifton MA et al. Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates. J Virol 2005; 79: 6516-6522. (Pubitemid 40617255)
25. Yang TC, Dayball K, Wan YH, Bramson J. Detailed analysis of the CD8+ T-cell response following adenovirus vaccination. J Virol 2003; 77: 13407-13411. (Pubitemid 37494336)
26. Millar J, Dissanayake D, Yang TC, Grinshtein N, Evelegh C, Wan Y et al. The magnitude of the CD8+ T cell response produced by recombinant virus vectors is a function of both the antigen and the vector. Cell Immunol 2007; 250: 55-67.
27. Tatsis N, Fitzgerald JC, Reyes-Sandoval A, Harris-McCoy KC, Hensley SE, Zhou D et al. Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines. Blood 2007; 110: 1916-1923. (Pubitemid 47443905)
28. Yang TC, Millar J, Groves T, Grinshtein N, Parsons R, Takenaka S et al. The CD8+ T cell population elicited by recombinant adenovirus displays a novel partially exhausted phenotype associated with prolonged antigen presentation that nonetheless provides long-term immunity. J Immunol 2006; 176: 200-210. (Pubitemid 43023264)
29. Overwijk WW, Lee DS, Surman DR, Irvine KR, Touloukian CE, Chan CC et al. Vaccination with a recombinant vaccinia virus encoding a 'self' antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. Proc Natl Acad Sci USA 1999; 96: 2982-2987. (Pubitemid 29148830)
30. Lane C, Leitch J, Tan X, Hadjati J, Bramson JL, Wan Y. Vaccination-induced autoimmune vitiligo is a consequence of secondary trauma to the skin. Cancer Res 2004; 64: 1509-1514. (Pubitemid 38235624)
31. Leitch J, Fraser K, Lane C, Putzu K, Adema GJ, Zhang QJ et al. CTL-dependent and -independent antitumor immunity is determined by the tumor not the vaccine. J Immunol 2004; 172: 5200-5205. (Pubitemid 38542016)
32. Kianizad K, Marshall LA, Grinshtein N, Bernard D, Margl R, Cheng S et al. Elevated frequencies of self-reactive CD8+ T cells following immunization with a xenoantigen are due to the presence of a heteroclitic CD4+ T-cell helper epitope. Cancer Res 2007; 67: 6459-6467. (Pubitemid 47037531)
33. Grinshtein N, Bridle B, Wan Y, Bramson JL. Neoadjuvant vaccination provides superior protection against tumor relapse following surgery compared with adjuvant vaccination. Cancer Res 2009; 69: 3979-3985.
34. Gallo P, Dharmapuri S, Nuzzo M, Maldini D, Iezzi M, Cavallo F et al. Xenogeneic immunization in mice using HER2 DNA delivered by an adenoviral vector. Int J Cancer 2005; 113: 67-77. (Pubitemid 39507312)
35. Park JM, Terabe M, Sakai Y, Munasinghe J, Forni G, Morris JC et al. Early role of CD4+ Th1 cells and antibodies in HER-2 adenovirus vaccine protection against autochthonous mammary carcinomas. J Immunol 2005; 174: 4228-4236. (Pubitemid 40396003)
36. Wang X, Wang JP, Rao XM, Price JE, Zhou HS, Lachman LB. Prime-boost vaccination with plasmid and adenovirus gene vaccines control HER2/neu+ metastatic breast cancer in mice. Breast Cancer Res 2005; 7: R580-R588.
37. Park JM, Terabe M, Steel JC, Forni G, Sakai Y, Morris JC et al. Therapy of advanced established murine breast cancer with a recombinant adenoviral ErbB-2/neu vaccine. Cancer Res 2008; 68: 1979-1987. (Pubitemid 351416585)
38. Drebin JA, Link VC, Greene MI. Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo. Oncogene 1988; 2: 273-277. (Pubitemid 18085307)
39. Umeshappa CS, Huang H, Xie Y, Wei Y, Mulligan SJ, Deng Y et al. CD4+ Th-APC with acquired peptide/MHC class I and II complexes stimulate type 1 helper CD4+ and central memory CD8+ T cell responses. J Immunol 2009; 182: 193-206.
40. Sas S, Chan T, Sami A, El-Gayed A, Xiang J. Vaccination of fiber-modified adenovirus-transfected dendritic cells to express HER-2/neu stimulates efficient HER-2/neu-specific humoral and CTL responses and reduces breast carcinogenesis in transgenic mice. Cancer Gene Ther 2008; 15: 655-666.
41. Wright P, Zheng C, Moyana T, Xiang J. Intratumoral vaccination of adenoviruses expressing fusion protein RM4/ tumor necrosis factor (TNF)-alpha induces significant tumor regression. Cancer Gene Ther 1998; 5: 371-379. (Pubitemid 128640026)
42. Carlsson G, Gullberg B, Hafstrom L. Estimation of liver tumor volume using different formulas-an experimental study in rats. J Cancer Res Clin Oncol 1983; 105: 20-23. (Pubitemid 13194363)
43. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792. (Pubitemid 32222155)
44. Miller F, Jones RF, Jacob J, Kong YC, Wei WZ. From breast cancer immunobiology to her-2 DNA vaccine and autoimmune sequelae. Breast Dis 2004; 20: 43-51. (Pubitemid 39600445)
45. Reilly RT, Gottlieb MB, Ercolini AM, Machiels JP, Kane CE, Okoye FI et al. HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice. Cancer Res 2000; 60: 3569-3576. (Pubitemid 30482178)
46. Czerniecki BJ, Koski GK, Koldovsky U, Xu S, Cohen PA, Mick R et al. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res 2007; 67: 1842-1852. (Pubitemid 46383411)
47. Ambrosino E, Spadaro M, Iezzi M, Curcio C, Forni G, Musiani P et al. Immunosurveillance of Erbb2 carcinogenesis in transgenic mice is concealed by a dominant regulatory T-cell self-tolerance. Cancer Res 2006; 66: 7734-7740. (Pubitemid 44289233)
48. Wall EM, Milne K, Martin ML, Watson PH, Theiss P, Nelson BH. Spontaneous mammary tumors differ widely in their inherent sensitivity to adoptively transferred T cells. Cancer Res 2007; 67: 6442-6450. (Pubitemid 47037529)
49. Whittington PJ, Piechocki MP, Heng HH, Jacob JB, Jones RF, Back JB et al. DNA vaccination controls Her-2+ tumors that are refractory to targeted therapies. Cancer Res 2008; 68: 7502-7511.
50. Harwerth IM, Wels W, Schlegel J, Muller M, Hynes NE. Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth. Br J Cancer 1993; 68: 1140-1145. (Pubitemid 23356666)
51. Knutson KL, Almand B, Dang Y, Disis ML. Neu antigennegative variants can be generated after neu-specific antibody therapy in neu transgenic mice. Cancer Res 2004; 64: 1146-1151. (Pubitemid 38176922)
52. Antonia S, Mule JJ, Weber JS. Current developments of immunotherapy in the clinic. Curr Opin Immunol 2004; 16: 130-136. (Pubitemid 38328713)
53. Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 2005; 54: 721-728. (Pubitemid 40977140)
54. Hudziak RM, Lewis GD, Winget M, Fendly BM, Shepard HM, Ullrich A. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 1989; 9: 1165-1172. (Pubitemid 19071685)
55. Nahta R, Esteva FJ. HER-2-targeted therapy: lessons learned and future directions. Clin Cancer Res 2003; 9: 5078-5084. (Pubitemid 37413555)
56. Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 2001; 61: 4744-4749. (Pubitemid 32691885)
57. Le XF, Claret FX, Lammayot A, Tian L, Deshpande D, LaPushin R et al. The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition. J Biol Chem 2003; 278: 23441-23450. (Pubitemid 36830161)
58. Jackson JG, St Clair P, Sliwkowski MX, Brattain MG. Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects. Cancer Res 2004; 64: 2601-2609. (Pubitemid 38523918)
59. Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL. Herceptin-induced inhibition of phosphatidylinositol- 3. kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 2002; 62: 4132-4141. (Pubitemid 34791085)
60. Mohsin SK, Weiss HL, Gutierrez MC, Chamness GC, Schiff R, Digiovanna MP et al. Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol 2005; 23: 2460-2468. (Pubitemid 47050836)
61. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000; 6: 443-446. (Pubitemid 30208162)
62. Gennari R, Menard S, Fagnoni F, Ponchio L, Scelsi M, Tagliabue E et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 2004; 10: 5650-5655. (Pubitemid 39180938)
63. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2- overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 719-726. (Pubitemid 34111379)
64. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17: 2639-2648. (Pubitemid 29415219)
65. Baselga J, Gianni L, Geyer C, Perez EA, Riva A, Jackisch C. Future options with trastuzumab for primary systemic and adjuvant therapy. Semin Oncol 2004; 31: 51-57. (Pubitemid 39370110)
66. Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005; 23: 3676-3685.
67. Valabrega G, Montemurro F, Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 2007; 18: 977-984. (Pubitemid 47050487)
68. Whenham N, D'Hondt V, Piccart MJ. HER2-positive breast cancer: from trastuzumab to innovatory anti-HER2 strategies. Clin Breast Cancer 2008; 8: 38-49. (Pubitemid 351346229)
69. Bengala C, Zamagni C, Pedrazzoli P, Matteucci P, Ballestrero A, Da Prada G et al. Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study. Br J Cancer 2006; 94: 1016-1020.
70. Disis ML, Bernhard H, Shiota FM, Hand SL, Gralow JR, Huseby ES et al. Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptidebased vaccines. Blood 1996; 88: 202-210. (Pubitemid 26230688)
71. Ladjemi MZ, Jacot W, Chardes T, Pelegrin A, Navarro- Teulon I. Anti-HER2 vaccines: new prospects for breast cancer therapy. Cancer Immunol Immunother 2010; 59: 1295-1312.
72. Baxevanis CN, Perez SA, Papamichail M. Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy. Cancer Immunol Immunother 2009; 58: 317-324.
73. Mittendorf EA, Storrer CE, Shriver CD, Ponniah S, Peoples GE. Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancer. Ann Surg Oncol 2006; 13: 1085-1098. (Pubitemid 44337968)
74. Disis ML, Wallace DR, Gooley TA, Dang Y, Slota M, Lu H et al. Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. J Clin Oncol 2009; 27: 4685-4692.
75. Benavides LC, Gates JD, Carmichael MG, Patil R, Holmes JP, Hueman MT et al. The impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin Cancer Res 2009; 15: 2895-2904.
76. Bruna-Romero O, Gonzalez-Aseguinolaza G, Hafalla JC, Tsuji M, Nussenzweig RS. Complete, long-lasting protection against malaria of mice primed and boosted with two distinct viral vectors expressing the same plasmodial antigen. Proc Natl Acad Sci USA 2001; 98: 11491-11496. (Pubitemid 32928756)
77. Hassett DE, Slifka MK, Zhang J, Whitton JL. Direct ex vivo kinetic and phenotypic analyses of CD8(+) T-cell responses induced by DNA immunization. J Virol 2000; 74: 8286-8291. (Pubitemid 30666677)
78. Garnett CT, Erdman D, Xu W, Gooding LR. Prevalence and quantitation of species C adenovirus DNA in human mucosal lymphocytes. J Virol 2002; 76: 10608-10616. (Pubitemid 35176177)
79. Gu Z, Belzer SW, Gibson CS, Bankowski MJ, Hayden RT. Multiplexed, real-time PCR for quantitative detection of human adenovirus. J Clin Microbiol 2003; 41: 4636-4641. (Pubitemid 37259769)
80. Karimi K, Boudreau JE, Fraser K, Liu H, Delanghe J, Gauldie J et al. Enhanced antitumor immunity elicited by dendritic cell vaccines is a result of their ability to engage both CTL and IFN gamma-producing NK cells. Mol Ther 2008; 16: 411-418. (Pubitemid 351168051)
81. Chan T, Sami A, El-Gayed A, Guo X, Xiang J. HER-2/neugene engineered dendritic cell vaccine stimulates stronger HER-2/neu-specific immune responses compared to DNA vaccination. Gene Ther 2006; 13: 1391-1402. (Pubitemid 44420634)
82. Bocangel D, Zheng M, Mhashilkar A, Liu Y, Ramesh R, Hunt KK et al. Combinatorial synergy induced by adenoviral- mediated mda-7 and Herceptin in Her-2+ breast cancer cells. Cancer Gene Ther 2006; 13: 958-968. (Pubitemid 44373796)